Safety of single-dose nevirapine for prevention of vertical transmission of human immunodeficiency virus infection | Zendy

MangalaBhaskar Murthy | Zendy; Bhaskar Krishnamurthy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety of single-dose nevirapine for prevention of vertical transmission of human immunodeficiency virus infection

Author(s) -

MangalaBhaskar Murthy,

Bhaskar Krishnamurthy

Publication year - 2011

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.77372

Subject(s) - nevirapine , virology , human immunodeficiency virus (hiv) , transmission (telecommunications) , medicine , immunology , computer science , viral load , antiretroviral therapy , telecommunications

Nevirapine administered as a single dose each to the mother and child within 72 h after birth is used to prevent vertical transmission of human immunodeficiency virus (HIV) under the prevention of parent to child transmission of HIV program (PPTCT). The efficacy of nevirapine in this regard has been proved beyond doubt, but there are unresolved questions about its safety. Hence, the primary objective of this study was to evaluate the safety of this regime.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research